Want to join the conversation?
Pharma firm $MDCO said that it has completed the patient enrollment in the ORION-1 study of PCSK9si along with its partner $ALNY. 480 patients with high cardiovascular risk and high bad cholesterol were enrolled in this study. Treatment results are anticipated by the end of 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.